Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: Mar 26, 2025
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea
Emrosi Initial Distribution Ongoing; First Prescriptions Filled
Read more at globenewswire.com6.35
+0.04 (+0.63%)
NASDAQ:FBIO (6/18/2025, 4:30:02 PM)
1.81
-0.02 (-1.09%)
Find more stocks in the Stock Screener
